LTX 001
Alternative Names: LTX-001Latest Information Update: 22 Nov 2024
Price :
$50 *
At a glance
- Originator Leal Therapeutics
- Class Antidepressants; Antipsychotics; Small molecules
- Mechanism of Action Glutaminase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Amyotrophic lateral sclerosis; Major depressive disorder; Schizophrenia
Most Recent Events
- 30 Oct 2024 Preclinical trials in Amyotrophic lateral sclerosis in USA (unspecified route) prior to October 2024 (Leal Therapeutics pipeline, October 2024)
- 30 Oct 2024 Preclinical trials in Major depressive disorder in USA (unspecified route) prior to October 2024 (Leal Therapeutics pipeline, October 2024)
- 30 Oct 2024 Preclinical trials in Schizophrenia in USA (unspecified route) prior to October 2024 (Leal Therapeutics pipeline, October 2024)